ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $114.5M rose 56.8% year over year, ahead of the +14.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1105.3% from the prior quarter. Over 3 fiscal years it compounded at +46.1% a year.

Context

  • Cost of revenue amounted to 49.0% of revenue in FY2025, up 8.3 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +56.8% holds above the trailing-twelve-month pace of +14.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$114.5M+1105.3% QoQ
Last fiscal yearDec 2025
$432.73M+72.9% YoY
LTMMar 2026
$314.64M+14.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+56.8%——
1 year+72.9%——
3-year CAGR+46.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
432.73M USD
Year-over-year change
+72.9%
4-year CAGR
+44.0%

Cost of Revenue vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.8% is the 3rd highest of 10, against a peer median of +7.3%.
  • Cost of revenue amounts to 34.1% of revenue for ANIP, versus a peer median of 49.0%.
ANIP Competitors
Cost of Revenue for ANIP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹167.45B INR+12.3%+16.2%50.5%
VTRSViatris Inc.LTM Jun 2026$9.6B USD+7.3%-1.7%65.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$8.23B USD-1.8%+1.5%47.5%
BHCBausch Health Companies Inc.LTM Jun 2026$3.06B USD+5.9%+8.4%28.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$1.89B USD+6.4%+9.8%60.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$379.4M USD+5.6%+13.3%52.7%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$314.64M USD+14.8%+46.1%34.1%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$313.15M USD+11.4%+7.6%39.3%
EOLSEvolus, Inc.LTM Mar 2026$103.98M USD+17.4%+21.1%34.5%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$93.03M USD—+7.0%68.8%
HROWHarrow Health, Inc.LTM Mar 2026$69.57M USD+28.3%+38.8%25.9%
Peer median (excluding ANIP) —+7.3%+9.1%49.0%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.